Copyright investors
Rigel Pharmaceuticals (RIGL) saw an improvement in its IBD SmartSelect Composite Rating Thursday, from 91 to 96. The new rating shows the stock is outpacing 96% of all stocks when it comes to the most important stock-picking criteria. The top-performing stocks tend to have a 95 or better grade as they begin to launch a significant move so be sure to keep that in mind when looking for the best stocks to buy and watch. Rigel Pharmaceuticals is currently forming a cup without handle, with a 43.72 buy point. See if the stock can break out in volume at least 40% higher than normal. The stock has an 80 EPS Rating, meaning its recent quarterly and annual earnings growth is outpacing 80% of all stocks. Its Accumulation/Distribution Rating of B- shows moderate buying by institutional investors over the last 13 weeks. In Q3, the company posted 109% earnings growth. Sales growth came in at 26%, down from 176% in the previous quarter. Rigel Pharmaceuticals holds the No. 16 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals (AUPH), Incyte (INCY) and argenx ADR (ARGX) are among the top 5 highly-rated stocks within the group. This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article. YOU MAY ALSO LIKE
